Table 1.
Patient characteristics by metastasis status
| Covariate | Level |
All patients (N = 200) |
Metastasis status | P‐value* | |
|---|---|---|---|---|---|
|
Met (N = 101) |
Non‐Met (N = 99) |
||||
| Age at diagnosis | Median (Range) | 61 (22‐93) | 59 (23‐93) | 63 (22‐89) | 0.163 |
| Sex | Female | 70 (35) | 33 (47.14) | 37 (52.86) | 0.486 |
| Male | 130 (65) | 68 (52.31) | 62 (47.69) | ||
| Grade | WD | 32 (16) | 3 (9.38) | 29 (90.63) | <0.001 |
| MD | 132 (66) | 75 (56.82) | 57 (43.18) | ||
| PD | 26 (13) | 13 (50) | 13 (50) | ||
| NK | 10 (5) | 10 (100) | 0 (0) | ||
| Stage | I | 41 (20.5) | 0 (0) | 41 (100) | <0.001 |
| II | 31 (15.5) | 0 (0) | 31 (100) | ||
| III | 29 (14.5) | 17 (58.62) | 12 (41.38) | ||
| IV | 99 (49.5) | 84 (84.85) | 15 (15.15) | ||
| T Stage | T1 | 65 (32.5) | 24 (36.92) | 41 (63.08) | 0.062 |
| T2 | 69 (34.5) | 38 (55.07) | 31 (44.93) | ||
| T3 | 29 (14.5) | 17 (58.62) | 12 (41.38) | ||
| T4 | 37 (18.5) | 22 (59.46) | 15 (40.54) | ||
| N Stage | N0 | 99 (49.5) | 0 (0) | 99 (100) | NA |
| N1 | 19 (9.5) | 19 (100) | 0 (0) | ||
| N2 | 74 (37) | 74 (100) | 0 (0) | ||
| N3 | 8 (4) | 8 (100) | 0 (0) | ||
| N Stage:binary | N0 | 99 (49.5) | 0 (0) | 99 (100) | NA |
| N1‐N3 | 101 (50.5) | 101 (100) | 0 (0) | ||
| Site | L | 61 (30.5) | 28 (45.9) | 33 (54.1) | <0.001 |
| OC | 101 (50.5) | 40 (39.6) | 61 (60.4) | ||
| OP | 38 (19) | 33 (86.84) | 5 (13.16) | ||
| Covariate | Level |
All patients (N = 167) |
Metastasis status | P‐value* | |
|---|---|---|---|---|---|
|
Met (N = 90) |
Non‐Met (N = 77) |
||||
| MVD:cut by ROC (High ≥ 40.667) | High | 65 (38.92) | 55 (84.62) | 10 (15.38) | <0.001 |
| Low | 102 (61.08) | 35 (34.31) | 67 (65.69) | ||
| MVD:cut by DFS optimal (High ≥ 53) | High | 26 (15.57) | 21 (80.77) | 5 (19.23) | 0.003 |
| Low | 141 (84.43) | 69 (48.94) | 72 (51.06) | ||
| MVD:cut by OS optimal (High ≥ 39.667) | High | 67 (40.12) | 56 (83.58) | 11 (16.42) | <0.001 |
| Low | 100 (59.88) | 34 (34) | 66 (66) | ||
| Covariate | Level |
All patients (N = 166) |
Metastasis status | P‐value* | |
|---|---|---|---|---|---|
|
Met (N = 90) |
Non‐Met (N = 77) |
||||
| LVD:cut by ROC (High ≥ 3.001) | High | 132 (79.52) | 64 (48.48) | 68 (51.52) | 0.003 |
| Low | 34 (20.48) | 26 (76.47) | 8 (23.53) | ||
| LVD:cut by DFS optimal (High ≥ 8.667) | High | 70 (42.17) | 36 (51.43) | 34 (48.57) | 0.538 |
| Low | 96 (57.83) | 54 (56.25) | 42 (43.75) | ||
| LVD:cut by OS optimal (High ≥ 2.667) | High | 137 (82.53) | 68 (49.64) | 69 (50.36) | 0.010 |
| Low | 29 (17.47) | 22 (75.86) | 7 (24.14) | ||
| Covariate | Median (Range) | Metastasis status | P‐value* | ||
|---|---|---|---|---|---|
| Met | Non‐Met | ||||
| MVD | 36 (11.67‐108) | 43.67 (16.33‐108) | 29.67 (11.67‐60) | <0.001 | |
| LVD | 7.42 (0‐51.67) | 7 (0‐51.67) | 7.83 (0‐32.33) | 0.154 | |
Data are presented as number of patients (%) or median (range).
*
The P‐value is calculated by Wilcoxon rank‐sum test for numerical covariates; and chi‐squared test or Fisher's exact test for categorical covariates, where appropriate.
Significant P‐value is bolded.